Text Size

GR Defect in Peripheral Blood Mononuclear Cells in COPD

This study has been completed.
Sponsor:
Collaborator:
AstraZeneca
Information provided by:
Imperial College London
ClinicalTrials.gov Identifier:
NCT00159237
First received: September 8, 2005
Last updated: August 12, 2008
Last verified: August 2008
History of Changes
  Purpose

T.to investigate a possible mechanism of the glucocorticosteroid receptors (GR) defect in patients with severe COPD by studying the effect of dexamethasone (Dex) on GR- binding, interleukin production (IL-6/IL-8) and MKP-1 expression in peripheral blood mononuclear cells blood (PBMC)


Condition Intervention
Chronic Obstructive Pulmonary Disease
 Procedure: blood test

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: GR Defect in Peripheral Blood Mononuclear Cells in COPD

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Imperial College London:

Estimated Enrollment: 30
Study Start Date: February 2005
Estimated Study Completion Date: December 2008
  Eligibility

Ages Eligible for Study:   35 Years to 85 Years
Genders Eligible for Study:   Both
Criteria

Inclusion Criteria:

  • Patients with severe (stage III, Gold) to very severe (stage IV, GOLD) COPD or subjects who are healthy smokers or subjects who are non-smokers
  • Written informed consent

Exclusion Criteria:

  • Current upper respiratory tract infections
  • Any significant disease or disorder (e.g. cardiovascular, pulmonary (other than asthma), gastrointestinal, liver, renal, neurological, musculoskeletal, endocrine, metabolic, malignant, psychiatric, major physical impairment) which, in the opinion of the investigator, may either put the subject at risk because of participation in the study, or may influence the results of the study, or the subjects ability to participate in the study
  • Subjects not considered capable, as judged by the investigator, of following instructions of the study, e.g. because of a history of alcohol or drug abuse or any other reason
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00159237

Locations
United Kingdom
Section of Airway Disease, Asthma Lab, Imperial College London, Royal Brompton Hospital
London, United Kingdom, SW3 6LY
Sponsors and Collaborators
Imperial College London
AstraZeneca
Investigators
Principal Investigator: Sergei A Kharitonov, MD PhD Imperial College London
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00159237     History of Changes
Other Study ID Numbers: D5899N00007
Study First Received: September 8, 2005
Last Updated: August 12, 2008
Health Authority: United Kingdom: Research Ethics Committee

Additional relevant MeSH terms:
Lung Diseases
Respiration Disorders
Pulmonary Disease, Chronic Obstructive
Lung Diseases, Obstructive
Respiratory Tract Diseases

ClinicalTrials.gov processed this record on May 19, 2013